BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
Go back to BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 9.31 +0.17 (1.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.14 | 52 Week High | $10.98 | |||
| Open | $9.18 | 52 Week Low | $1.63 | |||
| Day High | $9.50 | P/E | N/A | |||
| Day Low | $9.10 | EPS | $-0.68 | |||
| Volume | 5,144,626 | |||||
